Summary of Significant Accounting Policies (Details) - USD ($)		3 Months Ended	9 Months Ended
	Nov. 02, 2016	Sep. 30, 2016	Sep. 30, 2016
Summary of accounting policies
Impairment charge		$ 5,169,000	$ 5,169,000
Deferred tax benefit			(2,317,000)
Medivir
Summary of accounting policies
Consideration for sale	$ 12,000,000
Shape Pharmaceuticals
Summary of accounting policies
Fair value of assets		12,000,000	$ 12,000,000
Impairment charge		5,200,000
Deferred tax benefit		$ (2,300,000)